A unique blood-based diagnostic test for the earliest possible detection of cancer and genetic mutations.

Funding stage: Series A+

The investment teams managing the Fund have made investments in some revolutionary early-stage knowledge intensive companies, which are already changing the way we shop, live and work. Here’s a key example of the type of business the Fund looks to invest in.

What is it?

Biofidelity’s mission is to provide access to precise cancer diagnostics for all patients. They’ve developed a unique blood-based diagnostic test for the earliest possible detection of cancer and genetic mutations, including melanoma, liver, kidney and breast cancer.

They can detect these DNA abnormalities, even when the concentration of the cancer or mutant DNA is too low to be picked up by existing diagnostic methods.

Why we like it

Biofidelity’s three-hour rapid test is low cost, has higher sensitivity than other tests and can be run on standard PCR machines, common in all hospitals. It could allow the earliest possible detection of cancer, up to 18 months earlier than methods currently used, and enable real-time monitoring post diagnosis. This should reduce the cost of treatment, improve patient outcomes and significantly help to reduce the burden on healthcare systems.

What our fund managers say

“We’re not only excited by the disruptive and innovative technology that Biofidelity has developed, but also the multi-billion-dollar market opportunity for the application of the technology and the huge impact it could have on patient outcomes.”

– Luke Hakes – Partner, Octopus Ventures

Key risks

Investing in the Fund which invests in these types of companies is high risk. Don’t invest unless you’re prepared to lose all the money you invest. 

Shares in EIS-qualifying companies could fall or rise in value more than other shares listed on the main market of the London Stock Exchange.

More companies we’ve backed